I agree. This reads well. There are so many things going on, and revenue seems to be gaining traction. Once it achieves CF+, will support their drug development program (much like CUV). With ~30ml in cash, and a current revenue run rate of ~16ml, at a 47ml EV, puts it on ~3 times revenue. This looks like good value for a unique offering company with lots of levers to the upside.
Ann: Q3 FY24 Quarterly Investor Presentation, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.015(8.33%) |
Mkt cap ! $73.89M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.5¢ | 16.5¢ | $136.0K | 816.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 200000 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 27122 | 1 |
View Market Depth
| Last trade - 15.45pm 21/06/2024 (20 minute delay) ? |
| MAP (ASX) Chart |